Screener
Wave Life Sciences WVE Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Wave Life Sciences in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-324949
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $20,362 | $15,700 |
| Accrued expenses and other current liabilities | 18,242 | 26,564 |
| Current portion of deferred revenue | 8,703 | 44,440 |
| Current portion of operating lease liability | 3,508 | 8,361 |
| Total current liabilities | 50,815 | 95,065 |
| Long-term liabilities: | ||
| Deferred revenue, net of current portion | 13,904 | 7,798 |
| Operating lease liability, net of current portion | 40,082 | 9,405 |
Item 1. Financial Statements
FAQ
- What is Wave Life Sciences's operating lease liabilities (current)?
- Wave Life Sciences (WVE) reported operating lease liabilities (current) of $3.51M in Q2 2026.
- How has Wave Life Sciences's operating lease liabilities (current) changed year-over-year?
- Wave Life Sciences's operating lease liabilities (current) decreased by 56.9% year-over-year, from $8.14M to $3.51M.
- What is the long-term trend for Wave Life Sciences's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Wave Life Sciences's operating lease liabilities (current) has grown at a 17.6% compound annual growth rate (CAGR), from $3.71M to $8.36M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Wave Life Sciences's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude